GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viela Bio Inc (NAS:VIE) » Definitions » Equity-to-Asset

Viela Bio (Viela Bio) Equity-to-Asset : 0.89 (As of Dec. 2020)


View and export this data going back to 2019. Start your Free Trial

What is Viela Bio Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Viela Bio's Total Stockholders Equity for the quarter that ended in Dec. 2020 was $375.83 Mil. Viela Bio's Total Assets for the quarter that ended in Dec. 2020 was $423.26 Mil. Therefore, Viela Bio's Equity to Asset Ratio for the quarter that ended in Dec. 2020 was 0.89.

The historical rank and industry rank for Viela Bio's Equity-to-Asset or its related term are showing as below:

VIE' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.89   Med: 0.91   Max: 0.92
Current: 0.89

During the past 3 years, the highest Equity to Asset Ratio of Viela Bio was 0.92. The lowest was 0.89. And the median was 0.91.

VIE's Equity-to-Asset is not ranked
in the Biotechnology industry.
Industry Median: 0.67 vs VIE: 0.89

Viela Bio Equity-to-Asset Historical Data

The historical data trend for Viela Bio's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viela Bio Equity-to-Asset Chart

Viela Bio Annual Data
Trend Dec18 Dec19 Dec20
Equity-to-Asset
-1.35 0.92 0.89

Viela Bio Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.92 0.92 0.91 0.95 0.89

Competitive Comparison of Viela Bio's Equity-to-Asset

For the Biotechnology subindustry, Viela Bio's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Viela Bio's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viela Bio's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Viela Bio's Equity-to-Asset falls into.



Viela Bio Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Viela Bio's Equity to Asset Ratio for the fiscal year that ended in Dec. 2020 is calculated as

Equity to Asset (A: Dec. 2020 )=Total Stockholders Equity/Total Assets
=375.828/423.257
=0.89

Viela Bio's Equity to Asset Ratio for the quarter that ended in Dec. 2020 is calculated as

Equity to Asset (Q: Dec. 2020 )=Total Stockholders Equity/Total Assets
=375.828/423.257
=0.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Viela Bio  (NAS:VIE) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Viela Bio Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Viela Bio's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Viela Bio (Viela Bio) Business Description

Traded in Other Exchanges
N/A
Address
One MedImmune Way, First Floor, Area Two, Gaithersburg, MD, USA, 20878
Viela Bio Inc is a clinical-stage biotechnology company engaged in developing and commercializing transformative treatments for severe inflammation and autoimmune diseases. Its product inebilizumab, is a humanized monoclonal antibody, designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells.
Executives
Chris Nolet director C/O REVANCE THERAPEUTICS, INC., 7555 GATEWAY BOULEVARD, NEWARK CA 94560
Rachelle Suzanne Jacques director C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
Edward Hu director 10975 TORREY PINES ROAD, LA JOLLA CA 92037
Boyu Capital General Partner Iii, L.p. 10 percent owner SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Boyu Capital General Partner Iii, Ltd. 10 percent owner SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Boyu Capital Group Holdings Ltd. 10 percent owner SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Xyxy Holdings Ltd. 10 percent owner SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Boyu Capital Investment Management Ltd 10 percent owner SUITE 1501, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Boundless Meadow Ltd 10 percent owner SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Xiaomeng Tong director, 10 percent owner SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Yanling Cao director, 10 percent owner SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Boyu Capital Fund Iii, L.p. 10 percent owner C/O MAPLES CORPORATE SERVICES LIMITED BOX 309, UGLAND HOUSE GRAND CAYMAN E9 KYL-1104
Boyu Capital Opportunities Master Fund 10 percent owner CAYMAN CORPORATE CENTRE 27 HOSPITAL ROAD, GEORGE TOWN CAYMAN ISLANDS E9 KY1-9008
Zhengbin Yao director, officer: Chief Executive Officer 10301 STELLA LINK ROAD, HOUSTON TX 77025
William Ragatz officer: VP, Head of Commercial C/O VIELA BIO, INC., ONE MEDIMMUNE WAY FIRST FLOOR, AREA TWO GAITHERSBURG MD 20878